ArticleIranian journal of otorhinolaryngology2024
Epidemiological Study of Head and Neck Sarcomas.
Article in Iranian journal of otorhinolaryngology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Head and neck sarcomas are uncommon tumors that account for less than 1% of head and neck malignancies and fewer than 5% of all sarcomas. This study aims to assess the head and neck sarcomas pattern in Isfahan, Iran, compare its results with previous findings, and investigate treatment methods and the recurrence and survival rate. Materials and Methods: This study was done on 160 patients diagnosed with head and neck sarcomas between 2001 and 2020 in four medical centers in Isfahan, Iran. The patients with head and neck sarcoma confirmed by biopsy were included. Patient information included sex, age at diagnosis, and full characteristics of the mass. Disease recurrence and 2-year and 5-year overall survival (OS) were investigated by phone. Results: Among 160 patients, 94 (58.8%) were male. The mean age was 36.9 ± 23.2 years. The neck was the most reported location for sarcomas (N=34, 21.3%). Undifferentiated pleomorphic sarcoma was the most frequent histopathologic pattern (N=48, 30.0%). The brain and lungs were the most common destinations for metastasis. "Surgery and adjuvant therapy together" was the most common type of treatment (N=108, 68.8%). The 2-year and 5-year recurrence rates were N=100, 62.5%, and N=110, 68.8%, respectively. The 2-year and 5-year OS was N=103, 64.4%, and N=58, 36.6%, respectively. Eighty-nine patients have had metastasis (55.6%). Conclusions: Both 2-year and 5-year recurrence rates and OS were significantly correlated with metastasis. The OS within two years and five years were significantly higher in those treated only by "Surgery".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.